What did @cassie.jespersen actually say?
Surprisingly little about Wegovy, despite the hashtag. The transcript is almost entirely motivational language: "quitting is not an option," "I never give up," and variations on the same theme. There's no clinical claim, no dosing advice, no before-and-after numbers. Just a personal hype reel set against what appears to be a weight loss progress video.
That's worth noting up front, because 1.7 million viewers showed up expecting GLP-1 content and got a motivational speech. The Wegovy hashtag does the heavy lifting here, framing the whole thing as a semaglutide success story, even though the words themselves never mention the drug at all.
Does the science back this up?
The motivational framing, that persistence is what drives weight loss success, is partially supported by research, but it's more complicated than "I don't quit" suggests. The evidence on GLP-1 medications specifically complicates the pure willpower narrative.
A 2021 trial published in the New England Journal of Medicine (Wilding et al.) showed that semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks, with results largely independent of behavioral intensity scores at baseline. In other words, the drug worked even for people who weren't especially motivated going in. Separately, a 2023 review in Obesity Reviews (Lingvay et al.) found that adherence to GLP-1 therapy, not mindset per se, was the strongest predictor of sustained weight loss outcomes. Adherence is partly behavioral, yes, but it's also heavily influenced by side effect tolerance, insurance coverage, and prescriber follow-up.
Motivation matters. But framing GLP-1 results as a direct product of refusing to quit oversimplifies the pharmacology.
What did they get wrong (or right)?
Credit where it's due: Cassie isn't selling anything here. There's no affiliate code, no dose recommendation, no claim that Wegovy cures anything. The message is emotionally honest and she explicitly calls posting this "vulnerable." That's a healthier framing than the majority of GLP-1 content on TikTok, which tends toward miracle-story territory.
What's missing, and what matters, is context. The implicit message of the video is that her results came from not quitting. But for postpartum women specifically, weight loss involves hormonal shifts, breastfeeding status, sleep deprivation, and metabolic changes that no amount of determination fixes. A 2022 paper in the American Journal of Clinical Nutrition (Gunderson et al.) found that postpartum weight retention is strongly predicted by pre-pregnancy BMI, gestational weight gain, and lactation status, not self-reported motivation levels.
The video doesn't claim anything false outright. But the framing implies a cause-and-effect between mindset and results that the research doesn't fully support, especially when a prescription medication is part of the picture.
What should you actually know?
If you're considering Wegovy after seeing content like this, here's what the data actually says. Semaglutide works through appetite suppression and slowed gastric emptying, not by making you more disciplined. The Wilding et al. STEP 1 trial showed most participants regained significant weight within a year of stopping the medication, suggesting the drug is doing more work than the mindset.
For postpartum patients specifically, semaglutide is not currently approved for use while breastfeeding, and the safety data in that population is limited. The FDA label for Wegovy recommends against use during pregnancy and advises caution in the postpartum period for nursing mothers. If you're in that window, that conversation belongs with your OB or a licensed prescriber, not a TikTok comment section.
Persistence as a value is fine. But if you're drawn to this video because you're struggling to lose weight despite "not quitting," the issue may be physiological, not motivational. GLP-1 medications work on biology. They don't work harder because you believe in yourself more.
The bottom line
This video is more inspirational content than health misinformation. The claims are vague enough to be mostly harmless, and the creator deserves credit for not making specific medical claims. The bigger issue is what's implied: that willpower is the engine behind GLP-1 results. The pharmacology disagrees. Semaglutide is a powerful appetite-regulating drug. It is not a reward for having the right mindset.